Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase  

作　　者：YUAN Ting 袁婷(Peking Univ People's Hosp,Beijing 100044)

机构地区：[1]Peking Univ People's Hosp,Beijing 100044

出　　处：《China Medical Abstracts(Internal Medicine)》2020年第2期111-112,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To explore the efficacy and prognosis of nilotinib or dasatinib as second-or third-line treatment in patients with chronic myeloid leukemia(CML)in the chronic phase(CP)and accelerated phase(AP).Methods From January 2008 to November 2018,the data of CML patients who failed first-or second-line tyrosine kinase inhibitor(TKI)-therapy received nilotinib or dasatinib as second-line and third-line therapy were retrospectively reviewed.

关 键 词：PATIENTS MYELOID LEUKEMIA 

分 类 号：R733.72[医药卫生—肿瘤]